Comparative Pharmacology
Head-to-head clinical analysis: IDVYNSO versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDVYNSO versus TRABECTEDIN.
IDVYNSO vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Deslanoside
"Trabectedin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrabectedin + Acetyldigitoxin
"Trabectedin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent